CRISPR Therapeutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Jul '25 Jul 23, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Market Capitalization	6,252	3,360	4,972	3,183	5,799	10,818	Upgrade
Market Cap Growth	-46.65%	-32.44%	56.24%	-45.12%	-46.39%	198.74%	Upgrade
Enterprise Value	4,616	1,651	3,474	1,452	3,527	9,501	Upgrade
Last Close Price	68.14	39.36	62.60	40.65	75.78	153.11	Upgrade
PE Ratio	-	-	-	-	15.36	-	Upgrade
PS Ratio	154.45	90.03	13.40	2656.64	6.34	15045.33	Upgrade
PB Ratio	3.22	1.74	2.64	1.70	2.42	6.50	Upgrade
P/TBV Ratio	3.42	1.74	2.64	1.70	2.42	6.50	Upgrade
P/FCF Ratio	-	-	-	-	12.68	-	Upgrade
P/OCF Ratio	-	-	-	-	10.76	-	Upgrade
EV/Sales Ratio	122.52	44.26	9.36	1211.76	3.86	13213.93	Upgrade
EV/EBITDA Ratio	-	-	-	-	9.01	-	Upgrade
EV/EBIT Ratio	-	-	-	-	9.44	-	Upgrade
EV/FCF Ratio	-	-	-	-	7.71	-	Upgrade
Debt / Equity Ratio	0.12	0.12	0.13	0.13	0.09	0.04	Upgrade
Debt / EBITDA Ratio	-	-	-	-	0.53	-	Upgrade
Debt / FCF Ratio	-	-	-	-	0.49	-	Upgrade
Asset Turnover	0.02	0.02	0.17	0	0.40	0	Upgrade
Quick Ratio	15.53	22.00	17.47	15.08	19.92	18.05	Upgrade
Current Ratio	15.64	22.07	17.54	15.30	20.17	18.21	Upgrade
Return on Equity (ROE)	-19.71%	-19.20%	-8.17%	-30.42%	18.59%	-26.80%	Upgrade
Return on Assets (ROA)	-12.88%	-13.04%	-6.22%	-16.85%	10.20%	-15.30%	Upgrade
Return on Capital (ROIC)	-13.58%	-13.63%	-6.56%	-17.74%	10.73%	-16.30%	Upgrade
Return on Capital Employed (ROCE)	-	-	-	-	14.20%	-	Upgrade
Earnings Yield	-6.17%	-10.90%	-3.09%	-20.43%	6.51%	-3.23%	Upgrade
FCF Yield	-4.92%	-4.31%	-5.43%	-16.74%	7.89%	-2.37%	Upgrade
Buyback Yield / Dilution	-6.74%	-6.49%	-1.90%	3.29%	-21.90%	-15.84%	Upgrade

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q